Our commitment is to deliver novel, innovative and high quality science to meet the challenges faced by our clients in the development and manufacture of therapies and diagnostic tests for conditions such as cancer, Alzheimer’s and diabetes.
Why join our Scientific / R&D team?
Select your area of expertise within the Drug Development pipeline:
Almac Discovery is an independent, research driven drug discovery company dedicated to the development of novel and innovative therapeutics. Our multidisciplinary team of scientists use cutting edge research techniques to develop First in Class preclinical stage assets which are then licenced to pharmaceutical partners for further development. Key research themes include protein homeostasis (specifically focused on deubiquitinase enzymes) and next generation protein drug conjugates.
Staff in our Diagnostic Services business unit use their talent and expertise to develop tailored genomics-based diagnostic solutions in the areas of oncology, immunology, CNS and infection.
With exciting and varied career paths in biomarker discovery, assay development and validation, companion diagnostics (CDx) development and commercialisation and project management, Diagnostic Services is at the forefront of innovation in the area of stratified medicine.
API Services & Chemical Development
Our Sciences business unit focusses on the scale-up manufacture of Active Pharmaceutical Ingredient (API) and advanced intermediates destined for pre-clinical testing and toxicology studies, clinical trials and commercial production.
Our multi-disciplinary team-based approach involving staff in Chemistry, Chemical/Process Engineering, Analytical, Quality and Production departments, ensures the development of efficient processes that will save both time and money in getting new medicines to market.
Staff in Almac’s Pharma Services business unit provide optimum, fit-for-purpose and future-proof pharmaceutical drug product development solutions ranging from non-GMP Formulation Development to First-in-Human trials to scale up for late phase trials and commercial manufacture.
Scientists in our state-of-the-art, custom designed facilities within our Formulation Development, Production, Quality and Analytical Departments work on a diverse range of projects that support the manufacture and testing of drug products, typically solid oral dosage forms, throughout their lifecycle.
Analytical & Solid State Services
Staff in our Analytical and Solid State Services teams use their chemistry and biology expertise to support analysis of Active Pharmaceutical Ingredient (API) and drug product (finished product) across all phases of the drug development lifecycle, including commercial release.
From the development and validation of analytical methods and the analysis and stability testing of a range of product types, to gaining a full insight into the physicochemical properties of the API using polymorph, salt and cocrystal screening, our analytical scientists are making a valuable contribution to the development of new treatments for patients around the world.
Exceptional Industry Leading Knowledge
Meet some of Almac’s industry-leading experts.
Dr. Leeona Galligan
VP UK Operations, Diagnostic Services
Dr. Galligan is responsible for all UK based operations including commercial biomarker discovery, CLIA/FDA compliant analytical validation, downstream clinical testing, manufacturing and shipping of clinical specimen and release of controls and reagents for registrational clinical trials.
Dr. Diaz Perez brings considerable experience in research and development. He is responsible for Almac’s Solid State Chemistry and Physical Sciences business and tasked with strengthening the overarching chemical development strategy.
Dr. Knight is VP of Bioinformatics, Biostatistics and Informatics within Almac Diagnostic Services. Her remit also includes Assay Software Development for Clinical Trial Assays, Companion Diagnostic (CDx) devices and Data Management.
Prof. Moody is responsible for the development and application of platform technologies within both the Sciences and Arran businesses, in addition to supporting and directing commercialisation of new technology. He has direct operational responsibility for the Biocatalysis and Isotope Chemistry businesses and the R&D function within Arran.